Welcome to Celleron Therapeutics
Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer.
Our mission
Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer. Celleron’s vision is that the future of cancer therapy lies in the ability to match therapies to individual patients. We are achieving this precision medicine through our proprietary drugs, biomarkers, events, and trials.
David Kerr, CBE
Press releases
Clinical products
CXD101
Celleron’s proprietary drug, CXD101, is a dual mechanism HDAC inhibitor with multiple properties that differentiate it from competing compounds. CXD101 is a novel epigenetic immune-regulator which has the ability to enhance immune recognition of tumour cells.
CXD201
CXD201 is a proprietary topoisomerase inhibitor with multiple points of difference from competing products. CXD201 is derived from the homocamptothecin family, exhibiting a unique chemical composition and improved pharmacological properties.
CXD301
Emactuzumab (CXD301) is a humanised recombinant monoclonal antibody directed against the Colony Stimulating Factor-1 Receptor expressed on tumour-associated M2 macrophages. It effectively depletes CSF-1R positive macrophages in the tumour microenvironment.